Efficacy of repetitive transcranial magnetic stimulation in Parkinson's disease: A systematic review and meta-analysis of randomised controlled trials
Year: 2022
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Background Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive form of brain stimulation that positively regulates the motor and non-motor symptoms of Parkinson's disease (PD). Although, most reviews and meta-analysis have shown that rTMS intervention is effective in treating motor symptoms and depression, very few have used randomised controlled trials (RCTs) to analyse the efficacy of this intervention in PD. We aimed to review RCTs of rTMS in patients with PD to assess the efficacy of rTMS on motor and non-motor function in patients with PD. Methods In this systematic review and meta-analysis, we searched PubMed, MEDLINE and Web of Science databases for RCTs on rTMS in PD published between January 1, 1988 to January 1, 2022. Eligible studies included sham-controlled RCTs that used rTMS stimulation for motor or non-motor symptoms in PD. RCTs not focusing on the efficacy of rTMS in PD were excluded. Summary data were extracting from those RCTs by two investigators independently. We then calculated standardised mean difference with random-effect models. The main outcome included motor and non-motor examination of scales that were used in PD motor or non-motor assessment. This study was registered with PROSPERO, CRD42022329633. Findings Fourteen studies with 469 patients met the criteria for our meta-analysis. Twelve eligible studies with 381 patients were pooled to analyse the efficacy of rTMS on motor function improvement. The effect size on motor scale scores was 0.51 ( P < 0.0001) and were not distinctly heterogeneous (I 2 = 29%). Five eligible studies with 202 patients were collected to evaluate antidepressant-like effects. The effect size on depression scale scores was 0.42 ( P = 0.004), and were not distinctly heterogeneous (I 2 = 25%), indicating a significant anti-depressive effect (P = 0.004). The results suggest that high-frequency of rTMS on primary motor cortex (M1) is effective in improving motor symptoms; while the dorsolateral prefrontal cortex (DLPFC) may be a potentially effective area in alleviating depressive symptom. Interpretation The findings suggest that rTMS could be used as a possible adjuvant therapy for PD mainly to improve motor symptoms, but could have potential efficacy on depressive symptoms of PD. However, further investigation is needed. Funding The National Natural Science Foundation of China (NO: 81873777, 82071414), Initiated Foundation of Zhujiang Hospital (NO: 02020318005), Scientific Research Foundation of Guangzhou (NO: 202206010005), and Science and Technology Program of Guangdong of China (NO: 2020A0505100037).
Source: EClinicalMedicine
Authors: Wenjie Zhang, Bin Deng, Fen Xie, Hang Zhou, Ji-Feng Guo, Hong Jiang, Amy Sim, Beisha Tang, Qing Wang
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Keywords: repetitive transcranial magnetic stimulation, Parkinson's disease, motor symptoms, non-motor symptoms, depression, primary motor cortex, dorsolateral prefrontal cortex, high-frequency stimulation, adjuvant therapy, non-invasive brain stimulation, antidepressant effects, motor function improvement, safety and tolerability, medication adherence
Open Access status: gold
Estimated APC paid: $4,500
Awards: G2636277573, G4543927960, G4627068617
OpenAlex ID: W4288747424
